Early adherence to antiretroviral medication as a predictor of long-term HIV virological suppression: five-year follow up of an observational cohort.
AffiliationMédecins Sans Frontières, Cape Town, South Africa. firstname.lastname@example.org
MetadataShow full item record
AbstractOBJECTIVE: Previous studies have demonstrated a cross-sectional relationship between antiretroviral adherence and HIV virological suppression. We assessed the predictive value of baseline adherence in determining long-term virological failure. DESIGN: We assessed baseline adherence via an adherence questionnaire between administered to all consenting patients attending antiretroviral clinics in Khayelitsha township, South Africa, between May 2002 and March 2004. Virological status was ascertained after five years of follow up and multivariate analysis used to model associations of baseline variables and medication adherence with time to viral suppression or failure. RESULTS: Our adherence cohort comprised 207 patients, among whom 72% were female. Median age was 30 years and median CD4 count at initiation was 55 cells/mm(3). We found no statistically significant differences between baseline characteristics and early adherence groups. Multivariate analysis adjusting for baseline CD4 and age found that patients with suboptimal baseline adherence had a hazard ratio of 2.82 (95% CI 1.19-6.66, p = 0.018) for progression to virological failure compared to those whose baseline adherence was considered optimal. CONCLUSIONS: Our longitudinal study provides further confirmation of adherence as a primary determinant of subsequent confirmed virological failure, and serves as a reminder of the importance of initial early investments in adherence counseling and support as an effective way to maximize long-term treatment success.
- Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
- Authors: Van Vaerenbergh K
- Issue date: 2001
- Impact of previous virological treatment failures and adherence on the outcome of antiretroviral therapy in 2007.
- Authors: Ballif M, Ledergerber B, Battegay M, Cavassini M, Bernasconi E, Schmid P, Hirschel B, Furrer H, Rickenbach M, Opravil M, Weber R, Swiss HIV Cohort Study.
- Issue date: 2009 Dec 14
- Short communication. Association of the CCR5delta32 mutation with clinical response and >5-year survival following initiation of first triple antiretroviral regimen.
- Authors: Brumme ZL, Henrick BM, Brumme CJ, Hogg RS, Montaner JS, Harrigan PR
- Issue date: 2005
- Timeliness of clinic attendance is a good predictor of virological response and resistance to antiretroviral drugs in HIV-infected patients.
- Authors: Bastard M, Pinoges L, Balkan S, Szumilin E, Ferreyra C, Pujades-Rodriguez M
- Issue date: 2012
- Efficacy and safety of a switch to unboosted atazanavir in combination with nucleoside analogues in HIV-1-infected patients with virological suppression under antiretroviral therapy.
- Authors: Pavie J, Porcher R, Torti C, Medrano J, Castagna A, Valin N, Rusconi S, Ammassari A, Ghosn J, Delaugerre C, Molina JM, NEAT Unboosted Atazanavir Cohort Study Group.
- Issue date: 2011 Oct